Tesamorelin
Also Known As: Egrifta, Egrifta SV, TH9507, Tesamorelin acetate, Trans-3-hexenoic acid GHRH, Modified GHRH analog Egrifta, HIV lipodystrophy treatment peptide, GHRH analog tesamorelin, Liver fat peptide treatment, Cognitive GHRH analog, GHRH, tesa, tesamorelin acetate
Tesamorelin is a research-grade Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus targeting GHRH receptor studied in Muscle Growth & Performance research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Approved Drug - FDA and/or EMA approved with robust human trial data.
An FDA-approved growth-hormone-releasing hormone analog used to reduce visceral fat in HIV-associated lipodystrophy; banned in sport.
At A Glance
| Category | Muscle Growth & Performance |
|---|---|
| Compound Class | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism |
| Molecular Weight | 5135.9 Da |
| Amino Acid Sequence | hGHRH(1-44) with trans-3-hexenoyl |
| CAS Number | 218949-48-5 |
| Half-Life | ~26-38 minutes |
| WADA Status | prohibited |
| Evidence Tier | Approved Drug |
Mechanism Of Action
It is a highly stable GHRH analogue that binds to the pituitary to release growth hormone. Uniquely, its specific pulsatile effect heavily targets the breakdown of visceral adipose tissue (deep belly fat).
Studied For
- HIV-associated lipodystrophy (FDA approved)
- Hepatic fat / NAFLD research
- Cognition research in aging/HIV
- GH deficiency
- Body composition improvement
- Visceral adipose reduction
- Liver fat reduction
- GH axis stimulation
- IGF-1 elevation
- Cardiovascular lipid profile improvement
- Cognitive decline in aging HIV+ population
- Anti-aging via GH axis
- Non-alcoholic fatty liver disease
- Lean mass support
- visceral fat reduction
- belly fat
- HIV lipodystrophy
- muscle growth
- body composition
- lipid profile improvement
- cognitive function
Reported Research Findings
Strong human randomized trials show roughly 15 to 18 percent visceral-fat reduction over 26 weeks with reduced triglycerides and reduced liver fat. It is FDA-approved for HIV-associated lipodystrophy.
Safety And Handling Notes
Joint pain, injection-site reactions, peripheral edema, paresthesia, reduced glucose tolerance and elevated IGF-1.
Contraindicated in active malignancy, pituitary disorders, and pregnancy; monitor IGF-1 and glucose. Benefit reverses on discontinuation. WADA-prohibited (needs a therapeutic-use exemption).
Regulatory Status
FDA-approved (Egrifta) for HIV lipodystrophy; WADA S2.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.